Differential suppression of menstrual fluid prostaglandin F2a, prostaglandin E2, 6-keto prostaglandin F1a and thromboxane B2 by suprofen in women with primary dysmenorrhea.

Abstract

Eleven women with primary dysmenorrhea completed a randomized, double-blind, placebo-controlled, three-way cross-over study comparing 200 and 400mg suprofen. Menstrual fluid volume did not change. Mean+/-S.E.M. menstrual fluid PGF2a was significantly suppressed from 18.9+/-1.9 microg (placebo) to 10.9+/-1.7 and 9.3+/-2.1 microg with 200 and 400 mg suprofen, respectively (p=<0.005). PGE2 dropped from 7.8+/-0.9 to 4.6+/-0.8 and 4.6+/-1.1 microg (p=<0.05) and TxB2 from 17.5+/-4.3 to 7.5+/-2.9 and 3.6+/-1.3 microg (p=<0.01), respectively. 6-Keto PGF1a was significantly suppressed (2.7+/-0.4 to 1.9+/-0.5 microg, p=<0.025) with only 400 mg suprofen. Six subjects rated placebo poor and five fair to very good. In contrast, nine rated suprofen excellent to fair while two rated poor. Thus, suprofen was clinically effective but the differential suppression of prostanoids favors 200mg which spares 6-keto PGF1a.

• Authors: M Yusoff Dawood, Firyal S Khan-Dawood
• Journal: Prostaglandins & other lipid mediators (Prostaglandins Other Lipid Mediat) Vol. 83 Issue 1-2 Pg. 146-53 (Feb 2007) ISSN: 1098-8823 [Print] United States
• PMID: 17259081 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Prostaglandins
• Thromboxane B2
• 6-Ketoprostaglandin F1 alpha
• Suprofen
• Dinoprost
• Dinoprostone

Topics

• 6-Ketoprostaglandin F1 alpha (metabolism)
• Adult
• Anti-Inflammatory Agents, Non-Steroidal (pharmacology, therapeutic use)
• Body Fluids (drug effects, metabolism)
• Dinoprost (metabolism)
• Dinoprostone (metabolism)
• Dysmenorrhea (drug therapy, physiopathology)
• Female
• Humans
• Menstruation (drug effects)
• Prostaglandins (metabolism)
• Suprofen (pharmacology, therapeutic use)
• Thromboxane B2 (metabolism)